Blood Advances
Publisher: Elsevier · ISSN 2473-9529 · 99 articles
- Sustaining cell therapy quality through shared responsibility: a call for equitable FACT inspectorate participation
- American Society of Hematology 2026 guidelines for diagnosis of iron deficiency
- The complexity of provoked venous thromboembolism: one treatment plan does not fit all
- Reframing hematologic and thrombovascular care for transgender and gender-diverse individuals: a scoping review
- Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200
- Central nervous system involvement in children with hemophagocytic lymphohistiocytosis: an HLH-2004 study report
- Life-years saved by advances in blood cancer therapy: a retrospective analysis
- Duffy testing to benefit children’s population health: a cost-effectiveness analysis
- Chemotherapy-related anemia is regulated through caspase-1–mediated ROCK1 activation
- Molecular profiling and disease tracking of posttransplant lymphoproliferative disorders using cell-free DNA
- Comprehensive genetic characterization of adult BCR::ABL1-negative B-ALL by optical genome mapping and targeted NGS
- Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma
- Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs
- Second-line CD19 CAR T vs platinum salvage and autologous stem cell transplant for primary mediastinal B-cell lymphoma
- Assessment of the IPSS-M in chronic myelomonocytic leukemia
- The NLRC4 inflammasome drives myelodysplastic syndrome by linking epigenetic reprogramming and innate immune signaling
- Jagunal homolog 1 safeguards neutrophil immune function by preserving protein sialylation during differentiation
- Unmet needs despite standard-of-care prophylaxis in hemophilia A: improved outcomes after switching to efanesoctocog alfa
- Genetic and laboratory predictors of bleeding severity in FVII deficiency: insights from the PRO-RBDD and EN-RBD databases
- Activated platelets protect factor VIIIa from degradation by activated protein C and from subunit dissociation
- Optimizing outcomes and accessibility of matched sibling donor transplant for transfusion-dependent thalassemia in LMICs
- Clonal hematopoiesis in autoimmune hemolytic anemia
- Adaptive NK-cell dominance linked to HLH susceptibility in VEXAS syndrome
- The loss of miR-146a-5p contributes to ibrutinib resistance in mantle cell lymphoma
- Interpreting cord blood transplant outcomes in BMT CTN 1702
- Iron deficiency: cost-effectiveness and global applicability
- Umbilical cord blood donor outcomes in BMTCTN1702
- Fracturing ferric carboxymaltose from the iron pharmacopeia
- Sorror ML, Saber W, Logan B, et al. Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704. Blood Adv. 2025;9(13):3268-3280.
- Hu B, Reagan PM, Sehn LH, et al. Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study. Blood Adv. 2025;9(10):2489-2499.